HISTOPATHOLOGICAL AND BIOCHEMICAL MARKERS IN UTERINE LEIOMYOMAS AND THEIR IMPLICATIONS FOR MEDICAL TREATMENT: A MULTIDISCIPLINARY APPROACH FOR FINDING THE OUTCOMES OF TRANEXAMIC ACID
Main Article Content
Keywords
Histopathological Markers, Biochemical Markers, Uterine Leiomyomas, Implications
Abstract
Objective: To evaluate the role of histopathological and biochemical markers in uterine leiomyomas and assess the effectiveness of tranexamic acid in managing heavy menstrual bleeding (HMB) in affected patients.
Methods: A prospective observational study was conducted on 110 patients diagnosed with uterine leiomyomas and HMB. Patients were treated with tranexamic acid (1,000 mg three times daily) during menstruation for three cycles. Histopathological examination of fibroid tissue and biochemical marker analysis were performed. Outcomes included changes in menstrual blood loss (PBAC scores), hemoglobin levels, symptom relief, and fibroid size.
Results: Tranexamic acid significantly reduced menstrual blood loss by 52.5% (p < 0.001) and improved hemoglobin levels from 9.5 g/dL to 11.3 g/dL (p < 0.001). Patients reported a reduction in bleeding duration and pelvic pain. No significant change in fibroid size was observed. Histopathological findings showed typical features of fibroids, including smooth muscle proliferation and abnormal vascularization, while inflammatory markers (IL-6, TNF-α) decreased after treatment.
Conclusion: Tranexamic acid effectively reduces HMB in uterine leiomyoma patients without affecting fibroid size, making it a valuable non-hormonal treatment option.
References
2. Saxena N, Maio N, Crooks DR, Ricketts CJ, Yang Y, Wei MH, et al. SDHB-deficient cancers: The role of mutations that impair iron sulfur cluster delivery. J Natl Cancer Inst. 2016;108
3. Huang Y, Zhou Y, Chen X, Fang Q, Cai H, Xie M, et al. Uterine leiomyoma with fumarate hydratase deficiency: A case report. Medicine (Baltimore). 2021;100
4. Ooi A. Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research. Semin Cancer Biol. 2020;61:158–66.
5. Siegler L, Erber R, Burghaus S, Brodkorb T, Wachter D, Wilkinson N, et al. Fumarate hydratase (FH) deficiency in uterine leiomyomas: Recognition by histological features versus blind immunoscreening. Virchows Arch. 2018;472:789–96.
6. Papathomas TG, Oudijk L, Persu A, Gill AJ, van Nederveen F, Tischler AS, et al. SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: A multicenter interobserver variation analysis using virtual microscopy: A multinational study of the European Network for the Study of Adrenal Tumors (ENS@T). Mod Pathol. 2015;28:807–21.
7. Lee H, Shafiezadeh S, Singh R. Fumarase-deficient uterine leiomyoma: A case of a rare entity and surgical innovation. J Surg Case Rep. 2020;2020
8. Bennett JA, Weigelt B, Chiang S, Selenica P, Chen YB, Bialik A, et al. Leiomyoma with bizarre nuclei: A morphological, immunohistochemical and molecular analysis of 31 cases. Mod Pathol. 2017;30:1476–88.
9. Gregová M, Hojný J, Němejcová K, Bártů M, Mára M, Boudová B, et al. Leiomyoma with bizarre nuclei: A study of 108 cases focusing on clinicopathological features, morphology, and fumarate hydratase alterations. Pathol Oncol Res. 2020;26:1527–37.
10. Liu C, Dillon J, Beavis AL, Liu Y, Lombardo K, Fader AN, et al. Prevalence of somatic and germline mutations of fumarate hydratase in uterine leiomyomas from young patients. Histopathology. 2020;76:354–65.
11. Zhang X, Wang C, Shen D. The use of clinicopathological, immunohistochemistry and molecular detection in the diagnosis of fumarate hydratase-deficient uterine leiomyomas. Pathol Res Pract. 2024;253:154916.
12. Shi W, Liu Y, Aisagbonhi O, Roma AA, Hasteh F, Zare SY, et al. Fumarate hydratase-deficient leiomyoma of the uterine corpus: Comparative morphologic analysis of protein-deficient tumors with and without pathogenic germline fumarate hydratase gene mutations. Int J Surg Pathol. 2024;32:340–55.
13. Kopp RP, Stratton KL, Glogowski E, Schrader KA, Rau-Murthy R, Russo P, et al. Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma. Cancer. 2017;123:2452–8.
14. Park I, Shim YS, Go H, Hong BS, Lee JL. Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures. BMC Urol. 2019;19:51.
15. Yoo A, Tang C, Zucker M, Fitzgerald K, DiNatale RG, Rappold PM, et al. Genomic and metabolic hallmarks of SDH- and FH-deficient renal cell carcinomas. Eur Urol Focus. 2022;8:1278–88.
16. Gleeson JP, Nikolovski I, Dinatale R, Zucker M, Knezevic A, Patil S, et al. Comprehensive molecular characterization and response to therapy in fumarate hydratase-deficient renal cell carcinoma. Clin Cancer Res. 2021;27:2910–9.
17. Trpkov K, Hes O, Agaimy A, Bonert M, Martinek P, Magi-Galluzzi C, et al. Fumarate hydratase-deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary leiomyomatosis and renal cell carcinoma syndrome. Am J Surg Pathol. 2016;40:865–75.
18. Uimari O, Ahtikoski A, Kämpjärvi K, Butzow R, Järvelä IY, Ryynänen M, et al. Uterine leiomyomas in hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome can be identified through distinct clinical characteristics and typical morphology. Acta Obstet Gynecol Scand. 2021;100:2066–75.
19. Miettinen M, Felisiak-Golabek A, Wasag B, Chmara M, Wang Z, Butzow R, et al. Fumarase-deficient uterine leiomyomas: An immunohistochemical, molecular genetic, and clinicopathologic study of 86 cases. Am J Surg Pathol. 2016;40:1661–9.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr Fawad Hussain
Assistant Professor of Community Medicine. Niazi Medical & Dental College, Sargodha.
Dr Fareeha Naseer Syed
Assistant Professor of Pathology, CMH Multan Institute of Medical Sciences, Multan
Dr Muhammad Saeed
Associate Professor Biochemistry Department, Bolan Medical College, Quetta.
Dr Raza Farrukh
Assistant Professor, Department of Anaesthesia, Sargodha Medical College
Muhammad Adnan
Assistant Professor, Bakhtawar Amin Medical and Dental College, Multan
Dr Saifullah
SR Bakhtawar Amin Medical College, Multan